Johnson & Johnson (NYSE:JNJ) Shares Sold by 1900 Wealth Management LLC

1900 Wealth Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,621 shares of the company’s stock after selling 314 shares during the period. 1900 Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,047,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Narwhal Capital Management boosted its holdings in shares of Johnson & Johnson by 7.4% during the 3rd quarter. Narwhal Capital Management now owns 91,361 shares of the company’s stock worth $14,229,000 after purchasing an additional 6,324 shares during the last quarter. CBOE Vest Financial LLC grew its holdings in Johnson & Johnson by 66.9% in the 3rd quarter. CBOE Vest Financial LLC now owns 123,754 shares of the company’s stock valued at $19,275,000 after buying an additional 49,588 shares in the last quarter. Octavia Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 4.4% in the 3rd quarter. Octavia Wealth Advisors LLC now owns 11,537 shares of the company’s stock worth $1,797,000 after acquiring an additional 482 shares during the last quarter. Blue Chip Partners LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Blue Chip Partners LLC now owns 130,738 shares of the company’s stock worth $20,362,000 after acquiring an additional 2,064 shares during the period. Finally, Richwood Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. Richwood Investment Advisors LLC now owns 3,868 shares of the company’s stock valued at $602,000 after acquiring an additional 100 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.5 %

Johnson & Johnson stock traded up $2.28 during mid-day trading on Wednesday, reaching $153.52. 6,608,309 shares of the company’s stock were exchanged, compared to its average volume of 7,354,839. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a market cap of $369.47 billion, a P/E ratio of 9.57, a P/E/G ratio of 2.49 and a beta of 0.55. The company has a fifty day moving average of $151.73 and a 200-day moving average of $155.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the previous year, the firm posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 10.64 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.23%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Bank of America decreased their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, May 6th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.